billionsmatter
4 years ago
MAJOR COVERAGE OUT FROM OTC TIP REPORTER: #1 New Blockbuster Biotech Stock
Lobe Sciences Ltd. (GTSIF) Set to EXPLODE
As Wall Street & Silicon Valley Invest Heavily Into This
Explosive Space (This is like Cannabis in 2015-2016)
You Need to Get Ready for the “Shroom Boom” by
Pulling Up Lobe Sciences (GTSIF) Right Now
(GTSIF) Has a History of Making +1,067.72% Runs,
You Would Hate to Miss Out On Their Next One.
Dear Fellow Trader,
Immediately Turn Your Attention to Lobe Sciences (GTSIF)
Investor interest in this space is sending psychedelic stocks soaring to new heights. Do not Wait on Lobe Sciences (GTSIF).
If you are a new member, we’d like to “Welcome You” and start you off with our next potential breakout gainer Lobe Sciences (GTSIF).
For our existing members, I’d like to “Thank You” and cong·ratulate you on a string of massive winners… Starting with yesterday’s alert on (SPONF), which opened at .017 and ran to .028 on massive volume showing our members a potential intra-day gain of +64.70% in just a few hours.
Then today SPONF ran to a high of .04 running up +135.29% from yesterdays alert price of .017 and it ran up +354.54% from my alert at .0088 on Jan.19th.
And while we are at it, take a look at these recent gainers below...
RECENT GAINERS FROM 2021
February 8th, QSAM alerted at $.85 ran to $1.09 on February 9th for Potential Gains of +28.24% (Not bad for one day)
January 19th, SPONF alerted at $.0088 ran to $.0318 on January 26th for Potential Gains of +261.36%
January 12th, GWHP alerted at $.49 ran to $2.17 on January 21st for Potential Gains of +342.86%
January 6th, AIKI alerted at ($.84 pre-market) ran to ($2.65 pre-market) on Feb. 16th for Potential Gains of +215.47%
February 1st, FDCT alerted at $.47 ran to $.945 on February 10th for Potential Gains of +100%
Keep Reading So You Can See Why I Am So Excited About
Lobe Sciences (GTSIF) And It’s Heart-Pounding Potential For Your Portfolio
Our next alert brings us all the way to Vancouver, British Columbia where “The Prairies” have been a hub for psychedelic research since the 1950's.
Lobe Sciences (GTSIF) is a Vancouver-based life sciences company focused on the development of psychedelic medicines. They are focused on the research and the clinical development of psilocybin-based therapeutics for the treatment of mild Traumatic Brain Injuries (mTBIs) and Post-Traumatic Stress Disorder (PTSD).
Lobe is also working towards building devices and delivery mechanisms for the efficient application of medications.
Lobe Sciences owns acquired brands, intellectual property with respect to the psychedelics business whereas it generates its regular stream of cash flows through leasing office and production premises to cannabis processors and retailers.
The company has a highly experienced team and strong partnerships with universities that are helping it build on its research. We will discuss Lobe Science’s management team later in this report, but keep reading to see why we are so excited about Lobe Sciences (GTSIF)
Lobe Sciences (GTSIF) Core Offerings:
Psychedelics are known to have a strong application in the mental health space, particularly in PTSD as they have the ability to alter the perception and the mood of an individual and impact various cognitive processes.
Research has shown that many of these are safe to consume from a physiological standpoint and do not lead to dependence or addiction. Lobe Sciences is working towards building therapeutics that can make the optimum use of such psychedelics to help improve the mental health of patients suffering from PTSD of mTBIs.
The company has launched a preclinical research study using psilocybin (commonly known as Magic Mushrooms) and N-Acetylcysteine (“NAC”) for the treatment of mTBIs including various forms of concussion as well as PTSD.
NAC is basically a dietary supplement derived from the amino acid L-cysteine that has strong applications as an antioxidant for reduction of DNA damage, as an antidote for acetaminophen overdose, and for its liver-protective properties and to support a healthy functioning of the immune system.
Apart from combining NAC with psilocybin, Lobe is also working on patents associated with the combination of MDMA (commonly known as Ecstasy) and NAC for achieving a similar purpose.
Preclinical studies with respect to these combinations are being conducted by Lobe along with the scientists at University of Miami’s Miller School of Medicine under the leadership of Michael E. Hoffer, MD professor of otolaryngology and neurological surgery. More on this later when we discuss recent news.
Delivery Devices As A Product:
The second major aspect of Lobe’s research is associated with the delivery devices. The company is engaged in developing a nasal mist transducer device that can directly deliver the relevant medication to the olfactory bulb. It has the possibility of being combined with a virtual reality headset to have an augmented effect on the mentally ill individual.
Lobe is building this technology with engineering design and developmental support from Visionworks Engineering. The company will look to file a patent for this technology as well and it has a much faster timeline of development and should be ready over the coming 6 months. It is expected to have a strong application in this field.
VisionWorks Engineering provides medical device engineering services that meet US FDA and international regulatory bodies and standards. They work with medical device start-ups and industry leaders alike in the development of new medical devices.
Medical device companies can leverage VisionWorks Engineering expertise in bringing new medical devices to the market at any stage in the product development process. VisionWorks Engineering has helped their clients as they go through concept development, detail design, prototyping, testing, clinical trials, premarket approval, and final FDA approval for their new medical device products.
VisionWorks Engineering's medical device engineering experience covers a wide range of products. A few examples of the medical products they have helped to develop and bring to market include:
Portable HIV test system
Battery operated centrifuge
Disposable gauze applicator
Ophthalmic surgical system components
And now Lobe Sciences (GTSIF) and VisionWorks Engineering are working together on their nasal mist transducer device and will look to file a patent for this technology.
You see, what you need to realize here, is that Lobe Sciences (GTSIF) is not only developing the drugs using psilocybin, but they are also developing (and ideally patenting) the delivery methods as well.
Wall Street & Silicon Valley Leaders Are Rushing
to Support Psychedelic Medicine
As psilocybin boldly merges into modern pharmacopeia, the emerging field of psychedelic medicine continues forward amidst this electrifying renaissance. Pioneers such as MAPS, Usona Institute and Compass Pathways have been awarded the coveted “breakthrough status” for their psilocybin-based therapies by the US Food & Drug Administration. This designation marked a historic moment for the overall psychedelic revolution and has caught the attention of various notable investors from Wall Street and Silicon Valley.
Peter Thiel, the notable venture capitalist backer of Compass Pathways, is the co-founder of PayPal and one of Facebook’s first major investors. He is also the chairman of Palantir Technologies, which as of today has a market cap of over $54B dollars.
Thiel’s combined investments in Palantir and Compass Pathways highlights the significant shift in attention towards psychedelics from big players in Wall Street and Silicon Valley.
Looking at Thiel’s track record along with the significant attention towards psychedelics from big players in Wall Street and Silicon Valley, Thiel may be onto something by investing in the psilocybin sector!
UFC looks into Johns Hopkins study on psychedelic drugs as potential therapy for fighters
The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.
The promotion has been in contact with Johns Hopkins University about its psychedelic studies with an eye toward seeing if the drugs can be helpful for fighters dealing with brain issues, UFC president Dana White told MMA Junkie last month.
"We're diving into that," White said.
UFC senior vice president of health and performance Jeff Novitzky told ESPN that the interest came from a segment from HBO's "Real Sports" last month. Novitzky said White gave him a "directive" to look more into psychedelic research and he has been in contact with Johns Hopkins over the past few weeks.
The UFC has been a key funder of a professional athlete brain study being conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health, contributing another $1Mil last Month . Novitzky said the promotion could look to be a benefactor toward a psychedelic study with the added possibility of recruiting current or former UFC fighters to be part of the research.
"Dana said, 'Hey, find out what this is about,'" Novitzky said. "To see if it does help with some traumatic brain injury, addiction, mental-health problems. We want to be on board and we want to be first."
Johns Hopkins is the nation's leader in research on the therapeutic effects of psychedelics such as psilocybin (mushrooms) and LSD. The Johns Hopkins Center for Psychedelic & Consciousness Research gained regulatory approval from the U.S. government in 2000 and has produced more than 60 pieces of peer-reviewed research.
Currently, psilocybin and other psychedelics are classified by the U.S. government as illegal Schedule I drugs, defined as drugs with a high potential for abuse or drugs that have no medical uses.
However, views on psychedelics are changing.
Lega·lization of psychedelics for use in medicine is gaining momentum across the United States.
Advances in Lega·lization:
Lega·lization of psychedelics for use in medicine is gaining momentum across the United States. San Francisco, California, and Oakland and Santa Cruz, California, have decriminalized the use of psilocybin, the psychedelic molecule found in various mushrooms, while movements for lega·lization are gaining ground in Oregon and Iowa, among others. Decriminalize California recently teamed up with the Beckley Foundation to replicate Oakland’s success of decriminalization throughout the state of California.
An increasing number of researchers are turning their attention toward the study of psilocybin as a means to treat otherwise untreatable illnesses. The molecule’s ability to provide landmark treatment options for depression, post-traumatic stress disorder (PTSD), migraines and addiction is gaining widespread acceptance among medical professionals, unicorn investors and accredited institutions.
Potential Applications:
Historical data and new scientific studies suggest therapeutic benefits of psychedelics in many areas, including drug addiction, alcoholism, depression, migraines, smoking cessation and post-traumatic stress disorder (PTSD).
The market potential in these areas are significant. To reference just one of the above conditions, the mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.
According to the World Health Organization, 25% of the world’s populous will be afflicted by mental health and/or neurological disorders. Presently, approximately 450Mil people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide.
Additionally, PTSD affects approximately 2.2% of the U.S. population; 7.7mil people will have PTSD at some point in their lives. Recent published studies have demonstrated the safety and efficacy of certain psychedelics when administered in a medically supervised and monitored approach.
Lobe Sciences (GTSIF) is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
This could prove to be a major catalyst in propelling Lobe Sciences into becoming a key player in this space. Especially with any type of Patent or FDA Approval in the future.
Lobe Sciences (GTSIF) Gets “INCREDIBLE”
12 BUY RATINGS
Wall Streets leading provider of market data to the global financial, media, and commodity industries Barchart.com just Triggered an "INCREDIBLE" 12 BUY SIGNALS on Lobe Sciences (GTSIF) across the Short-Term Indicators, Medium-Term Indicators and even the Long-Term Indicators.
What You need to keep in mind is that BarChart just triggered these 12 BUY SIGNALS after (GTSIF) has already run +1,067.72% within the past year. You Would Hate to Miss Out On Their Next One.
This would be like turning $5,000 into $53,350… And I don’t know anyone who would want to miss out on that.
Lobe Sciences (GTSIF) Has a Very Accomplished Managed Team
That is Ready to Advance the Company and Drive Shareholder Value.
MANAGEMENT TEAM:
PHILLIP J. YOUNG - CEO & Director
Mr. Young is an analytical and results driven life sciences executive who has successfully managed public and private companies through product development, international growth, commercialization and M&A transactions. He has served as a Director and Chief Executive Officer for public companies for the past 20 years where he has created significant shareholder value, built integrated scientific, manufacturing, and commercial operations, directed successful M&A transactions and was responsible for generating more than $900M through acquisitions and equity financings. Mr. Young started his management career in the biopharmaceutical industry at Genentech Inc. where he was responsible for their cardiovascular and endocrine product launches sales and marketing.
BRIAN ZASITKO - Chief Financial Officer
Brian has over 13 years of experience across a variety of private and public sector companies in the cannabis, agriculture, manufacturing, and utility industries. He has extensive experience in financial reporting and corporate governance, as well as in the capital markets. Previously, Brian was a manager at Ernst & Young LLP, where he obtained his CPA, CA designation.
MAGHSOUD DARIANI - Chief Science Officer
Concurrent to leading science and technology efforts at LOBE, Maghsoud is also President and CEO of Semorex Inc. – a privately held company focused on the discovery and development of novel therapeutics for cancer. Prior to joining Semorex, Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage, then successfully negotiated the sale of the company in February 2003. Prior to Focus, Maghsoud was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, he was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names.
Dr. MARK A. GEYER PHD. - Science Advisor
Dr. Geyer is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. Since receiving his doctorate in Psychology in 1972, he has focused on basic research addressing the behavioral and neurobiological effects of psychedelics and other psychoactive drugs. Dr. Geyer is respected internationally for his research. He has published over 470 peer-reviewed papers, including many addressing the mechanisms subserving the effects of psychostimulants, psychedelics, and entactogens. Dr. Geyer’s broad experience as a researcher, grant reviewer, journal editor, and teacher lends invaluable scientific and professional expertise to our Company.
JONATHAN GILBERT - Executive Chairman
Most recently, Jonathan was the founder and CEO at Tassili LifeSciences, Corp., a biotech firm conducting research utilizing Psilocybin. Tassili was successfully acquired by a public company in March of 2020. He was also the founder and CEO of Scythian Biosciences, Inc. from December of 2014 through May of 2018. Scythian was a publicly traded research and development company in Canada focusing on the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination, as well as strategic investments and partnerships across cultivation, distribution, and retail of legal Cannabis. Prior to founding Scythian Biosciences, from January 2013 to December 2014, Gilbert was Marketing Officer for Commonwealth Oppo·rtunity Capital, GP, a hedge fund based in Greenwich, Connecticut. From October of 1995 until December of 2012, Jonathan was the owner and operator of Gilbert Capital Management, Corp., a full service private wealth management firm
LEIGHTON BOCKING – Director
Leighton has been working in the capital markets for over15 years. His primary role has been as an independent corporate development consultant in addition to holding various directorship positions. Leighton has been particularly focused on financing and structuring companies. An active investor, he started in the industry at Canaccord before moving to the public company side of the business.
MICHAEL PETTER - Director
Michael is an accomplished leader and entrepreneur in the psychedelics and cannabis industry, co-founding and acting as a director of several companies that successfully completed M&A transactions. He holds a Bachelors in Computer Science from London University, is a Chartered Engineer and private pilot. Since January 2009, he has been the Managing Director of Eyvo eProcurement Solutions, a US-based private company that is a leading eProcurement provider in the SaaS space. He also runs a business mentoring program that assists businesses and individuals with change management. Mike was co-founder and director of Eleusian Biosciences Corp., which the Company acquired in July 2020. He also co-founded and was a director of Tassili Life Sciences Corp. which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Petter has independent board experience being chairman of a compensation committee and as a member of an audit committee. His executive advisory skills focus on providing guidance on strategy, operations, finance, and logistics.
5 Potential Catalyst That Could Send Shares of
Lobe Sciences (GTSIF) Soaring This Week.
Potential Catalyst #1 Lobe Sciences Ltd.(GTSIF): Recently appointed Chief Medical Officer, Maghsoud Dariani, is not only one of the most sought-after experts in psychedelic medicine, but—as president of Focus Pharmaceuticals—he has already managed the development and FDA approval of similar products. As you can imagine, having someone on board who has already been through the entire FDA cycle and come out the other end successfully is a huge advantage for Lobe (CSE:LOBE | OTC:GTSIF)
Potential Catalyst #2 Lobe Sciences Ltd.(GTSIF): has been active with acquisitions Thanks to its acquisition of Eleusian Biosciences in July 2020, Lobe Sciences already has five provisional patent applications for unique combinations of psychedelics and medical devices to be used in the treatment of PTSD and mTBI.
Potential Catalyst #3 Lobe Sciences Ltd.(GTSIF): Wall Street & Silicon Valley Invest Heavily Into This Explosive Space with notable venture capitalist Peter Thiel even getting into the mix with his investment in Compass Pathways. So is Mr. Wonderful, Kevin O'Leary as he recently invested into a psychedelic company citing the potential of its drugs to address problems like depression, alcoholism, and opioid addiction, issues that haven’t seen medical innovations in almost three decades.
Potential Catalyst #4 Lobe Sciences Ltd.(GTSIF): Wall Streets leading provider of market data to the global financial, media, and commodity industries Barchart.com just Triggered an "INCREDIBLE" 12 BUY SIGNALS across the Short-Term Indicators, Medium-Term Indicators and even the Long-Term Indicators.
Potential Catalyst #5 Lobe Sciences Ltd.(GTSIF): Has a history of making BIG MOVES. From last May's low price of $.0158, the stock has run as much as +1,067.72% in a few short months when it hit a high of $.1845. (GTSIF) has pretty pulled back a little bit in the beginning of February when it's RSI dropped all the way down below .34 which has since reversed and is heading in the right direction would be signaling that another massive breakout is coming.
This could be the chance to take advantage of a company in a practically untapped market which is exhibiting strong growth potential, extreme diversity, and a highly-favorable technical setup!
LOBE SCIENCES (CSE:LOBE | OTC:GTSIF) just pulled back to an Attractive Price and Could be setting up for its Next Potential Major Breakout to the Upside, if their RSI cross-over .70 there is No-Telling what could happen.
You need to be ready “First Thing” Thursday morning.
Do not wait on Lobe Sciences (GTSIF). This stock trades on the US and Canadian Markets, so there could be more investors or traders who will be looking to gobble up shares as soon as the market opens tomorrow morning.
You need to have Lobe Sciences (GTSIF) up on your screen (First Thing) Thursday morning! Do not waste time.
Do not miss out on LOBE SCIENCES.
Sincerely,
Editor In Chief, OTCtipReporter Team
billionsmatter
4 years ago
Latest short report on GTSIF https://www.otcshortreport.com/company/GTSIF
Quite a bit over past 30 days. Have a look.
Feb 02 NA NA NA 577,056 109,840 19.03
Feb 01 NA NA NA 1,167,460 492,744 42.21
Jan 29 NA NA NA 1,215,485 450,733 37.08
Jan 28 NA NA NA 4,286,885 1,599,457 37.31
Jan 27 NA NA NA 2,570,877 833,844 32.43
Jan 26 NA NA NA 1,087,853 236,060 21.70
Jan 25 NA NA NA 952,153 574,398 60.33
Jan 22 NA NA NA 1,110,643 950,676 85.60
Jan 21 NA NA NA 450,092 169,334 37.62
Jan 20 NA NA NA 569,426 411,786 72.32
Jan 19 NA NA NA 435,373 178,869 41.08
Jan 15 NA NA NA 350,399 114,130 32.57
Jan 14 NA NA NA 866,109 535,322 61.81
Jan 13 NA NA NA 313,813 202,993 64.69
Jan 12 NA NA NA 449,774 257,941 57.35
Jan 11 NA NA NA 674,198 243,780 36.16
Jan 08 NA NA NA 502,120 256,172 51.02
Jan 07 NA NA NA 345,667 121,293 35.09
Jan 06 NA NA NA 608,142 372,443 61.24
Jan 05 NA NA NA 384,389 149,698 38.94
Jan 04 NA NA NA 851,122 486,178 57.12
Level up your trading with our powerful tools and real-time insights all in one place.
Ask ADVFN Intelligence (AI)
Mrogers23
2 years ago
trader_ron
2 years ago
Renee
2 years ago
mopartuck
4 years ago
TrendTrade2016
4 years ago
KOGT
4 years ago
beebread
4 years ago
OptimusPrime555
4 years ago
Hot Features
Premium
